nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—rheumatoid arthritis—ankylosing spondylitis	0.751	1	CtDrD
Penicillamine—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.141	0.714	CbGbCtD
Penicillamine—SLCO1B1—Methotrexate—ankylosing spondylitis	0.0566	0.286	CbGbCtD
Penicillamine—Guillain-Barre syndrome—Methotrexate—ankylosing spondylitis	0.00149	0.0287	CcSEcCtD
Penicillamine—Myasthenia gravis—Dexamethasone—ankylosing spondylitis	0.0011	0.0213	CcSEcCtD
Penicillamine—Myasthenia gravis—Betamethasone—ankylosing spondylitis	0.0011	0.0213	CcSEcCtD
Penicillamine—Atrophy—Prednisolone—ankylosing spondylitis	0.00109	0.0211	CcSEcCtD
Penicillamine—Atrophy—Triamcinolone—ankylosing spondylitis	0.001	0.0194	CcSEcCtD
Penicillamine—Atrophy—Methylprednisolone—ankylosing spondylitis	0.000999	0.0193	CcSEcCtD
Penicillamine—Atrophy—Dexamethasone—ankylosing spondylitis	0.000909	0.0176	CcSEcCtD
Penicillamine—Atrophy—Betamethasone—ankylosing spondylitis	0.000909	0.0176	CcSEcCtD
Penicillamine—Lupus erythematosus—Triamcinolone—ankylosing spondylitis	0.000876	0.017	CcSEcCtD
Penicillamine—Alveolitis allergic—Methotrexate—ankylosing spondylitis	0.000826	0.016	CcSEcCtD
Penicillamine—Leukaemia—Methotrexate—ankylosing spondylitis	0.000801	0.0155	CcSEcCtD
Penicillamine—Atrophy—Prednisone—ankylosing spondylitis	0.000792	0.0153	CcSEcCtD
Penicillamine—Trauma—Prednisolone—ankylosing spondylitis	0.000746	0.0144	CcSEcCtD
Penicillamine—Trauma—Triamcinolone—ankylosing spondylitis	0.000686	0.0133	CcSEcCtD
Penicillamine—Trauma—Methylprednisolone—ankylosing spondylitis	0.000684	0.0132	CcSEcCtD
Penicillamine—Trauma—Betamethasone—ankylosing spondylitis	0.000622	0.012	CcSEcCtD
Penicillamine—Trauma—Dexamethasone—ankylosing spondylitis	0.000622	0.012	CcSEcCtD
Penicillamine—Systemic lupus erythematosus—Triamcinolone—ankylosing spondylitis	0.00059	0.0114	CcSEcCtD
Penicillamine—Optic neuritis—Prednisolone—ankylosing spondylitis	0.000577	0.0112	CcSEcCtD
Penicillamine—Trauma—Prednisone—ankylosing spondylitis	0.000542	0.0105	CcSEcCtD
Penicillamine—Peptic ulcer—Prednisolone—ankylosing spondylitis	0.000531	0.0103	CcSEcCtD
Penicillamine—Optic neuritis—Triamcinolone—ankylosing spondylitis	0.000531	0.0103	CcSEcCtD
Penicillamine—Optic neuritis—Methylprednisolone—ankylosing spondylitis	0.00053	0.0102	CcSEcCtD
Penicillamine—Pulmonary fibrosis—Methotrexate—ankylosing spondylitis	0.00049	0.00948	CcSEcCtD
Penicillamine—Peptic ulcer—Triamcinolone—ankylosing spondylitis	0.000488	0.00945	CcSEcCtD
Penicillamine—Peptic ulcer—Methylprednisolone—ankylosing spondylitis	0.000487	0.00943	CcSEcCtD
Penicillamine—Optic neuritis—Dexamethasone—ankylosing spondylitis	0.000482	0.00932	CcSEcCtD
Penicillamine—Optic neuritis—Betamethasone—ankylosing spondylitis	0.000482	0.00932	CcSEcCtD
Penicillamine—Interstitial pneumonia—Methotrexate—ankylosing spondylitis	0.000446	0.00863	CcSEcCtD
Penicillamine—Peptic ulcer—Betamethasone—ankylosing spondylitis	0.000443	0.00857	CcSEcCtD
Penicillamine—Peptic ulcer—Dexamethasone—ankylosing spondylitis	0.000443	0.00857	CcSEcCtD
Penicillamine—Appetite absent—Methotrexate—ankylosing spondylitis	0.000433	0.00838	CcSEcCtD
Penicillamine—Optic neuritis—Prednisone—ankylosing spondylitis	0.000419	0.00811	CcSEcCtD
Penicillamine—Rash erythematous—Betamethasone—ankylosing spondylitis	0.000387	0.00748	CcSEcCtD
Penicillamine—Rash erythematous—Dexamethasone—ankylosing spondylitis	0.000387	0.00748	CcSEcCtD
Penicillamine—Peptic ulcer—Prednisone—ankylosing spondylitis	0.000386	0.00747	CcSEcCtD
Penicillamine—Vasculitis—Prednisolone—ankylosing spondylitis	0.000364	0.00704	CcSEcCtD
Penicillamine—Eruption—Methotrexate—ankylosing spondylitis	0.000351	0.00678	CcSEcCtD
Penicillamine—Leukocytosis—Methylprednisolone—ankylosing spondylitis	0.000347	0.00671	CcSEcCtD
Penicillamine—Extravasation—Betamethasone—ankylosing spondylitis	0.00034	0.00657	CcSEcCtD
Penicillamine—Extravasation—Dexamethasone—ankylosing spondylitis	0.00034	0.00657	CcSEcCtD
Penicillamine—Vasculitis—Triamcinolone—ankylosing spondylitis	0.000334	0.00647	CcSEcCtD
Penicillamine—Vasculitis—Methylprednisolone—ankylosing spondylitis	0.000334	0.00646	CcSEcCtD
Penicillamine—Neuropathy—Prednisolone—ankylosing spondylitis	0.000333	0.00645	CcSEcCtD
Penicillamine—Bone marrow depression—Methotrexate—ankylosing spondylitis	0.000319	0.00618	CcSEcCtD
Penicillamine—Leukocytosis—Dexamethasone—ankylosing spondylitis	0.000315	0.0061	CcSEcCtD
Penicillamine—Leukocytosis—Betamethasone—ankylosing spondylitis	0.000315	0.0061	CcSEcCtD
Penicillamine—Neuropathy—Triamcinolone—ankylosing spondylitis	0.000307	0.00593	CcSEcCtD
Penicillamine—Neuropathy—Methylprednisolone—ankylosing spondylitis	0.000306	0.00592	CcSEcCtD
Penicillamine—Interstitial lung disease—Methotrexate—ankylosing spondylitis	0.000305	0.00589	CcSEcCtD
Penicillamine—Vasculitis—Dexamethasone—ankylosing spondylitis	0.000304	0.00587	CcSEcCtD
Penicillamine—Vasculitis—Betamethasone—ankylosing spondylitis	0.000304	0.00587	CcSEcCtD
Penicillamine—Thrombophlebitis—Prednisolone—ankylosing spondylitis	0.000298	0.00576	CcSEcCtD
Penicillamine—Injury—Prednisolone—ankylosing spondylitis	0.00028	0.00542	CcSEcCtD
Penicillamine—Neuropathy—Dexamethasone—ankylosing spondylitis	0.000278	0.00538	CcSEcCtD
Penicillamine—Neuropathy—Betamethasone—ankylosing spondylitis	0.000278	0.00538	CcSEcCtD
Penicillamine—Leukocytosis—Prednisone—ankylosing spondylitis	0.000275	0.00531	CcSEcCtD
Penicillamine—Thrombophlebitis—Triamcinolone—ankylosing spondylitis	0.000274	0.0053	CcSEcCtD
Penicillamine—Thrombophlebitis—Methylprednisolone—ankylosing spondylitis	0.000273	0.00528	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Methylprednisolone—ankylosing spondylitis	0.000272	0.00526	CcSEcCtD
Penicillamine—Vasculitis—Prednisone—ankylosing spondylitis	0.000264	0.00511	CcSEcCtD
Penicillamine—Injury—Triamcinolone—ankylosing spondylitis	0.000258	0.00499	CcSEcCtD
Penicillamine—Injury—Methylprednisolone—ankylosing spondylitis	0.000257	0.00498	CcSEcCtD
Penicillamine—Thrombophlebitis—Betamethasone—ankylosing spondylitis	0.000248	0.00481	CcSEcCtD
Penicillamine—Thrombophlebitis—Dexamethasone—ankylosing spondylitis	0.000248	0.00481	CcSEcCtD
Penicillamine—Extravasation—Methotrexate—ankylosing spondylitis	0.000247	0.00478	CcSEcCtD
Penicillamine—Proteinuria—Methotrexate—ankylosing spondylitis	0.000245	0.00475	CcSEcCtD
Penicillamine—Neuropathy—Prednisone—ankylosing spondylitis	0.000242	0.00469	CcSEcCtD
Penicillamine—Protein urine present—Methotrexate—ankylosing spondylitis	0.000242	0.00468	CcSEcCtD
Penicillamine—Glossitis—Methotrexate—ankylosing spondylitis	0.000234	0.00453	CcSEcCtD
Penicillamine—Injury—Dexamethasone—ankylosing spondylitis	0.000234	0.00453	CcSEcCtD
Penicillamine—Injury—Betamethasone—ankylosing spondylitis	0.000234	0.00453	CcSEcCtD
Penicillamine—Muscular weakness—Prednisolone—ankylosing spondylitis	0.000227	0.0044	CcSEcCtD
Penicillamine—Vasculitis—Methotrexate—ankylosing spondylitis	0.000221	0.00427	CcSEcCtD
Penicillamine—Pancreatitis—Prednisolone—ankylosing spondylitis	0.000218	0.00422	CcSEcCtD
Penicillamine—Thrombophlebitis—Prednisone—ankylosing spondylitis	0.000216	0.00419	CcSEcCtD
Penicillamine—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.000209	0.00404	CcSEcCtD
Penicillamine—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.000209	0.00403	CcSEcCtD
Penicillamine—Asthma—Triamcinolone—ankylosing spondylitis	0.000205	0.00396	CcSEcCtD
Penicillamine—Injury—Prednisone—ankylosing spondylitis	0.000204	0.00394	CcSEcCtD
Penicillamine—Aplastic anaemia—Methotrexate—ankylosing spondylitis	0.000202	0.00392	CcSEcCtD
Penicillamine—Pancreatitis—Triamcinolone—ankylosing spondylitis	0.000201	0.00389	CcSEcCtD
Penicillamine—Pancreatitis—Methylprednisolone—ankylosing spondylitis	0.0002	0.00388	CcSEcCtD
Penicillamine—Mouth ulceration—Methotrexate—ankylosing spondylitis	0.000195	0.00377	CcSEcCtD
Penicillamine—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000195	0.00377	CcSEcCtD
Penicillamine—Muscular weakness—Betamethasone—ankylosing spondylitis	0.00019	0.00367	CcSEcCtD
Penicillamine—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.00019	0.00367	CcSEcCtD
Penicillamine—Lymphadenopathy—Methotrexate—ankylosing spondylitis	0.000183	0.00355	CcSEcCtD
Penicillamine—Thrombophlebitis—Methotrexate—ankylosing spondylitis	0.000181	0.0035	CcSEcCtD
Penicillamine—Haemoglobin—Prednisolone—ankylosing spondylitis	0.000179	0.00347	CcSEcCtD
Penicillamine—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.000179	0.00346	CcSEcCtD
Penicillamine—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.000179	0.00346	CcSEcCtD
Penicillamine—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000178	0.00345	CcSEcCtD
Penicillamine—Hepatic failure—Methotrexate—ankylosing spondylitis	0.000174	0.00337	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.000166	0.00321	CcSEcCtD
Penicillamine—Muscular weakness—Prednisone—ankylosing spondylitis	0.000165	0.0032	CcSEcCtD
Penicillamine—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.000165	0.00319	CcSEcCtD
Penicillamine—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000164	0.00318	CcSEcCtD
Penicillamine—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.000164	0.00317	CcSEcCtD
Penicillamine—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000164	0.00316	CcSEcCtD
Penicillamine—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.000162	0.00314	CcSEcCtD
Penicillamine—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.000162	0.00314	CcSEcCtD
Penicillamine—Pancreatitis—Prednisone—ankylosing spondylitis	0.000159	0.00307	CcSEcCtD
Penicillamine—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.00015	0.00289	CcSEcCtD
Penicillamine—Haemoglobin—Betamethasone—ankylosing spondylitis	0.00015	0.00289	CcSEcCtD
Penicillamine—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000149	0.00288	CcSEcCtD
Penicillamine—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000149	0.00288	CcSEcCtD
Penicillamine—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000148	0.00287	CcSEcCtD
Penicillamine—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000143	0.00277	CcSEcCtD
Penicillamine—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000141	0.00274	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000141	0.00273	CcSEcCtD
Penicillamine—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00014	0.0027	CcSEcCtD
Penicillamine—Asthma—Methotrexate—ankylosing spondylitis	0.000135	0.00262	CcSEcCtD
Penicillamine—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000135	0.00261	CcSEcCtD
Penicillamine—Angiopathy—Betamethasone—ankylosing spondylitis	0.000135	0.00261	CcSEcCtD
Penicillamine—Eosinophilia—Methotrexate—ankylosing spondylitis	0.000134	0.00259	CcSEcCtD
Penicillamine—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000133	0.00257	CcSEcCtD
Penicillamine—Alopecia—Dexamethasone—ankylosing spondylitis	0.000131	0.00254	CcSEcCtD
Penicillamine—Alopecia—Betamethasone—ankylosing spondylitis	0.000131	0.00254	CcSEcCtD
Penicillamine—Haemoglobin—Prednisone—ankylosing spondylitis	0.00013	0.00252	CcSEcCtD
Penicillamine—Haemorrhage—Prednisone—ankylosing spondylitis	0.00013	0.00251	CcSEcCtD
Penicillamine—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000128	0.00249	CcSEcCtD
Penicillamine—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000121	0.00235	CcSEcCtD
Penicillamine—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000121	0.00234	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00012	0.00233	CcSEcCtD
Penicillamine—Renal failure—Methotrexate—ankylosing spondylitis	0.000119	0.00229	CcSEcCtD
Penicillamine—Stomatitis—Methotrexate—ankylosing spondylitis	0.000118	0.00227	CcSEcCtD
Penicillamine—Angiopathy—Prednisone—ankylosing spondylitis	0.000118	0.00227	CcSEcCtD
Penicillamine—Haematuria—Methotrexate—ankylosing spondylitis	0.000115	0.00222	CcSEcCtD
Penicillamine—Alopecia—Prednisone—ankylosing spondylitis	0.000114	0.00221	CcSEcCtD
Penicillamine—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000114	0.00221	CcSEcCtD
Penicillamine—Mental disorder—Prednisone—ankylosing spondylitis	0.000113	0.0022	CcSEcCtD
Penicillamine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000113	0.00218	CcSEcCtD
Penicillamine—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000113	0.00218	CcSEcCtD
Penicillamine—Anxiety—Betamethasone—ankylosing spondylitis	0.00011	0.00213	CcSEcCtD
Penicillamine—Anxiety—Dexamethasone—ankylosing spondylitis	0.00011	0.00213	CcSEcCtD
Penicillamine—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000109	0.00211	CcSEcCtD
Penicillamine—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000108	0.00209	CcSEcCtD
Penicillamine—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000107	0.00207	CcSEcCtD
Penicillamine—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000106	0.00205	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000106	0.00205	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000106	0.00205	CcSEcCtD
Penicillamine—Anaemia—Prednisone—ankylosing spondylitis	0.000104	0.00202	CcSEcCtD
Penicillamine—Agitation—Prednisone—ankylosing spondylitis	0.000104	0.00201	CcSEcCtD
Penicillamine—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000103	0.002	CcSEcCtD
Penicillamine—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000103	0.002	CcSEcCtD
Penicillamine—Tinnitus—Methotrexate—ankylosing spondylitis	0.000101	0.00195	CcSEcCtD
Penicillamine—Anorexia—Betamethasone—ankylosing spondylitis	0.000101	0.00195	CcSEcCtD
Penicillamine—Anorexia—Dexamethasone—ankylosing spondylitis	0.000101	0.00195	CcSEcCtD
Penicillamine—Urticaria—Prednisolone—ankylosing spondylitis	0.000101	0.00195	CcSEcCtD
Penicillamine—Angiopathy—Methotrexate—ankylosing spondylitis	9.82e-05	0.0019	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	9.63e-05	0.00186	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	9.63e-05	0.00186	CcSEcCtD
Penicillamine—Arthralgia—Prednisone—ankylosing spondylitis	9.6e-05	0.00186	CcSEcCtD
Penicillamine—Anxiety—Prednisone—ankylosing spondylitis	9.57e-05	0.00185	CcSEcCtD
Penicillamine—Alopecia—Methotrexate—ankylosing spondylitis	9.57e-05	0.00185	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	9.53e-05	0.00184	CcSEcCtD
Penicillamine—Mental disorder—Methotrexate—ankylosing spondylitis	9.49e-05	0.00184	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisolone—ankylosing spondylitis	9.33e-05	0.00181	CcSEcCtD
Penicillamine—Urticaria—Triamcinolone—ankylosing spondylitis	9.25e-05	0.00179	CcSEcCtD
Penicillamine—Urticaria—Methylprednisolone—ankylosing spondylitis	9.23e-05	0.00179	CcSEcCtD
Penicillamine—Dysgeusia—Methotrexate—ankylosing spondylitis	9.23e-05	0.00179	CcSEcCtD
Penicillamine—Body temperature increased—Triamcinolone—ankylosing spondylitis	9.21e-05	0.00178	CcSEcCtD
Penicillamine—Decreased appetite—Betamethasone—ankylosing spondylitis	9.19e-05	0.00178	CcSEcCtD
Penicillamine—Decreased appetite—Dexamethasone—ankylosing spondylitis	9.19e-05	0.00178	CcSEcCtD
Penicillamine—Skin disorder—Prednisone—ankylosing spondylitis	8.94e-05	0.00173	CcSEcCtD
Penicillamine—Anorexia—Prednisone—ankylosing spondylitis	8.77e-05	0.0017	CcSEcCtD
Penicillamine—Anaemia—Methotrexate—ankylosing spondylitis	8.71e-05	0.00169	CcSEcCtD
Penicillamine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	8.58e-05	0.00166	CcSEcCtD
Penicillamine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	8.56e-05	0.00166	CcSEcCtD
Penicillamine—Leukopenia—Methotrexate—ankylosing spondylitis	8.44e-05	0.00163	CcSEcCtD
Penicillamine—Urticaria—Dexamethasone—ankylosing spondylitis	8.4e-05	0.00162	CcSEcCtD
Penicillamine—Urticaria—Betamethasone—ankylosing spondylitis	8.4e-05	0.00162	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	8.39e-05	0.00162	CcSEcCtD
Penicillamine—Body temperature increased—Betamethasone—ankylosing spondylitis	8.35e-05	0.00162	CcSEcCtD
Penicillamine—Body temperature increased—Dexamethasone—ankylosing spondylitis	8.35e-05	0.00162	CcSEcCtD
Penicillamine—Arthralgia—Methotrexate—ankylosing spondylitis	8.02e-05	0.00155	CcSEcCtD
Penicillamine—Decreased appetite—Prednisone—ankylosing spondylitis	8e-05	0.00155	CcSEcCtD
Penicillamine—Rash—Prednisolone—ankylosing spondylitis	7.99e-05	0.00155	CcSEcCtD
Penicillamine—Dermatitis—Prednisolone—ankylosing spondylitis	7.98e-05	0.00154	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	7.97e-05	0.00154	CcSEcCtD
Penicillamine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	7.95e-05	0.00154	CcSEcCtD
Penicillamine—Thrombocytopenia—Methotrexate—ankylosing spondylitis	7.53e-05	0.00146	CcSEcCtD
Penicillamine—Nausea—Prednisolone—ankylosing spondylitis	7.52e-05	0.00146	CcSEcCtD
Penicillamine—Skin disorder—Methotrexate—ankylosing spondylitis	7.47e-05	0.00145	CcSEcCtD
Penicillamine—Vomiting—Triamcinolone—ankylosing spondylitis	7.41e-05	0.00143	CcSEcCtD
Penicillamine—Vomiting—Methylprednisolone—ankylosing spondylitis	7.39e-05	0.00143	CcSEcCtD
Penicillamine—Rash—Triamcinolone—ankylosing spondylitis	7.34e-05	0.00142	CcSEcCtD
Penicillamine—Dermatitis—Triamcinolone—ankylosing spondylitis	7.34e-05	0.00142	CcSEcCtD
Penicillamine—Anorexia—Methotrexate—ankylosing spondylitis	7.33e-05	0.00142	CcSEcCtD
Penicillamine—Rash—Methylprednisolone—ankylosing spondylitis	7.33e-05	0.00142	CcSEcCtD
Penicillamine—Dermatitis—Methylprednisolone—ankylosing spondylitis	7.32e-05	0.00142	CcSEcCtD
Penicillamine—Urticaria—Prednisone—ankylosing spondylitis	7.31e-05	0.00141	CcSEcCtD
Penicillamine—Body temperature increased—Prednisone—ankylosing spondylitis	7.28e-05	0.00141	CcSEcCtD
Penicillamine—Diarrhoea—Betamethasone—ankylosing spondylitis	7.23e-05	0.0014	CcSEcCtD
Penicillamine—Diarrhoea—Dexamethasone—ankylosing spondylitis	7.23e-05	0.0014	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	7.01e-05	0.00136	CcSEcCtD
Penicillamine—Nausea—Triamcinolone—ankylosing spondylitis	6.92e-05	0.00134	CcSEcCtD
Penicillamine—Nausea—Methylprednisolone—ankylosing spondylitis	6.9e-05	0.00134	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisone—ankylosing spondylitis	6.78e-05	0.00131	CcSEcCtD
Penicillamine—Vomiting—Dexamethasone—ankylosing spondylitis	6.72e-05	0.0013	CcSEcCtD
Penicillamine—Vomiting—Betamethasone—ankylosing spondylitis	6.72e-05	0.0013	CcSEcCtD
Penicillamine—Decreased appetite—Methotrexate—ankylosing spondylitis	6.69e-05	0.00129	CcSEcCtD
Penicillamine—Rash—Dexamethasone—ankylosing spondylitis	6.66e-05	0.00129	CcSEcCtD
Penicillamine—Rash—Betamethasone—ankylosing spondylitis	6.66e-05	0.00129	CcSEcCtD
Penicillamine—Dermatitis—Dexamethasone—ankylosing spondylitis	6.66e-05	0.00129	CcSEcCtD
Penicillamine—Dermatitis—Betamethasone—ankylosing spondylitis	6.66e-05	0.00129	CcSEcCtD
Penicillamine—Diarrhoea—Prednisone—ankylosing spondylitis	6.3e-05	0.00122	CcSEcCtD
Penicillamine—Nausea—Betamethasone—ankylosing spondylitis	6.28e-05	0.00121	CcSEcCtD
Penicillamine—Nausea—Dexamethasone—ankylosing spondylitis	6.28e-05	0.00121	CcSEcCtD
Penicillamine—Urticaria—Methotrexate—ankylosing spondylitis	6.11e-05	0.00118	CcSEcCtD
Penicillamine—Body temperature increased—Methotrexate—ankylosing spondylitis	6.08e-05	0.00118	CcSEcCtD
Penicillamine—Vomiting—Prednisone—ankylosing spondylitis	5.85e-05	0.00113	CcSEcCtD
Penicillamine—Rash—Prednisone—ankylosing spondylitis	5.8e-05	0.00112	CcSEcCtD
Penicillamine—Dermatitis—Prednisone—ankylosing spondylitis	5.8e-05	0.00112	CcSEcCtD
Penicillamine—Hypersensitivity—Methotrexate—ankylosing spondylitis	5.67e-05	0.0011	CcSEcCtD
Penicillamine—Nausea—Prednisone—ankylosing spondylitis	5.47e-05	0.00106	CcSEcCtD
Penicillamine—Diarrhoea—Methotrexate—ankylosing spondylitis	5.26e-05	0.00102	CcSEcCtD
Penicillamine—Vomiting—Methotrexate—ankylosing spondylitis	4.89e-05	0.000946	CcSEcCtD
Penicillamine—Rash—Methotrexate—ankylosing spondylitis	4.85e-05	0.000938	CcSEcCtD
Penicillamine—Dermatitis—Methotrexate—ankylosing spondylitis	4.85e-05	0.000937	CcSEcCtD
Penicillamine—Nausea—Methotrexate—ankylosing spondylitis	4.57e-05	0.000884	CcSEcCtD
